Oxidized methionine melanoma epitopes

One of the most promising alternatives to chemotherapy in cancer treatment is immunotherapy, particularly, peptide-based immunotherapy in which synthetic peptides derived from tumor-specific antigens are used to trigger an immune response to specifically target cancer cells. Here using custom nanoLC-MS/MS based workflows we examine the possible presentation of peptide-based oxidative variants in complex with Major Histocompatibility Complex (MHC) class I proteins at the surface of melanoma cells. The deposited data contains the raw files associated with mild acidic elutions (MAE) of MHC class I associated peptides from various melanoma cell lines. These were analysed using Data Independent Acquisition (DIA), employing a custom method for MS/MS fragmentation of the native and Met-oxidative modifications of a tyrosinase derived peptide (YMDGTMSQV denoted as YMD peptide). The data contains also the raw files referring to the nanoLC-MS/MS analysis of HPLC purified fractions of various oxidative derivatives of the YMD peptide but also of MAGE-10 native and oxidized forms.